PL404247A1 - Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis - Google Patents

Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis

Info

Publication number
PL404247A1
PL404247A1 PL404247A PL40424713A PL404247A1 PL 404247 A1 PL404247 A1 PL 404247A1 PL 404247 A PL404247 A PL 404247A PL 40424713 A PL40424713 A PL 40424713A PL 404247 A1 PL404247 A1 PL 404247A1
Authority
PL
Poland
Prior art keywords
pertussis
bordetella pertussis
oligosugar
los
infections caused
Prior art date
Application number
PL404247A
Other languages
English (en)
Inventor
Sabina Koj
Tomasz Niedziela
Czesław Ługowski
Original Assignee
Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością filed Critical Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL404247A priority Critical patent/PL404247A1/pl
Priority to EP14744634.8A priority patent/EP3003389B1/en
Priority to PCT/IB2014/061944 priority patent/WO2014195881A1/en
Priority to ES14744634T priority patent/ES2729398T3/es
Priority to US14/896,222 priority patent/US9878051B2/en
Publication of PL404247A1 publication Critical patent/PL404247A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6087—Polysaccharides; Lipopolysaccharides [LPS]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Przedmiotem wynalazku jest immunogenny i nietoksyczny glikokoniugat zawierający oligocukier LOS Bordetella pertussis i toksynę krztuśca, sposób wytwarzania takiego glikokoniugatu, kompozycja farmaceutyczna, kompozycja szczepionki zawierająca taki glikokoniugat oraz zastosowanie takiego glikokoniugatu. Glikokoniugat ten jest preparowany jako składnik szczepionki chroniącej przeciwko infekcjom powodowanym przez Bordetella pertussis.
PL404247A 2013-06-07 2013-06-07 Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis PL404247A1 (pl)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PL404247A PL404247A1 (pl) 2013-06-07 2013-06-07 Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
EP14744634.8A EP3003389B1 (en) 2013-06-07 2014-06-04 Bordetella pertussis los-derived oligosaccharide with pertussis toxin glycoconjugate and its application in the prophylaxis and treatment of infections caused by bordetella pertussis
PCT/IB2014/061944 WO2014195881A1 (en) 2013-06-07 2014-06-04 Bordetella pertussis los-derived oligosaccharide with pertussis toxin glycoconjugate and its application in the prophylaxis and treatment of infections caused by bordetella pertussis
ES14744634T ES2729398T3 (es) 2013-06-07 2014-06-04 Glucoconjugado de oligosacárido procedente de LOS con la toxina tosferínica de Bordetella pertussis y su aplicación en la profilaxis y el tratamiento de infecciones causadas por Bordetella pertussis
US14/896,222 US9878051B2 (en) 2013-06-07 2014-06-04 Bordetella pertussis LOS-derived oligosaccharide with pertussis toxin glycoconjugate and its application in the prophylaxis and treatment of infections caused by Bordetella pertussis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL404247A PL404247A1 (pl) 2013-06-07 2013-06-07 Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis

Publications (1)

Publication Number Publication Date
PL404247A1 true PL404247A1 (pl) 2014-12-08

Family

ID=51229947

Family Applications (1)

Application Number Title Priority Date Filing Date
PL404247A PL404247A1 (pl) 2013-06-07 2013-06-07 Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis

Country Status (5)

Country Link
US (1) US9878051B2 (pl)
EP (1) EP3003389B1 (pl)
ES (1) ES2729398T3 (pl)
PL (1) PL404247A1 (pl)
WO (1) WO2014195881A1 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3283102A4 (en) * 2015-04-16 2018-10-03 Inventprise, LLC. Bordetella pertussis immunogenic vaccine compositions
CN104906569A (zh) * 2015-05-20 2015-09-16 北京智飞绿竹生物制药有限公司 一种百日咳疫苗制剂及其联合疫苗
CN110672732B (zh) * 2018-07-03 2022-12-02 岛津企业管理（中国）有限公司 百日咳毒素产品和百白破疫苗中活性蛋白的测定方法
CU20180159A7 (es) * 2018-12-28 2020-10-20 Chengdu Olisynn Biotechnology Co Ltd Derivados de oligosacáridos sintéticos como vacuna contra la bordetella pertussis
EP3799884A1 (en) * 2019-10-01 2021-04-07 GlaxoSmithKline Biologicals S.A. Immunogenic compositions

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471954A3 (en) 1990-08-13 1993-03-03 American Cyanamid Company Immunogenic conjugates of nontoxic oligosaccharide derived from bordetella pertussis lipooligosaccharide
US5445817A (en) 1992-08-21 1995-08-29 The United States Of America As Represented By The Department Of Health And Human Services Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
US5856122A (en) 1993-08-24 1999-01-05 University Of Alberta Modification of pertussis toxin
WO2008013735A2 (en) 2006-07-21 2008-01-31 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Methods for conjugation of oligosaccharides or polysaccharides to protein carriers through oxime linkages via 3-deoxy-d-manno-octulsonic acid
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
WO2012106251A2 (en) * 2011-01-31 2012-08-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Pertussis vaccine
PL223203B1 (pl) 2012-08-31 2016-10-31 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Sposób identyfikacji chemotypów lipopolisacharydowych bakterii Gram-ujemnych z zastosowaniem metody MALDI-TOF MS

Also Published As

Publication number Publication date
ES2729398T3 (es) 2019-11-04
EP3003389B1 (en) 2019-02-20
EP3003389A1 (en) 2016-04-13
US9878051B2 (en) 2018-01-30
US20160114051A1 (en) 2016-04-28
WO2014195881A1 (en) 2014-12-11

Similar Documents

Publication Publication Date Title
MX395525B (es) Composiciones inmunogenicas para usar en vacunas neumococicas.
CL2011002639A1 (es) Cepa bacteriana de mycoplasma bovis atenuada avirulenta; composicion inmunogenica que la comprende; y uso para fabricar un medicamento para infecciones producidas por m. bovis.
CL2019003264A1 (es) Formulaciones para vacunas contra la neoplasia y métodos para preparar las mismas. (divisional solicitud 201703151)
CL2018000320A1 (es) Coadyuvantes basados en aceite (divisional de solicitud 201600650)
NZ751197A (en) Compounds and methods of treating infections
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
MX392525B (es) Composiciones inmunogenicas para su uso en vacunas neumococicas
WO2015095811A8 (en) Combination therapy with neoantigen vaccine
BR112016012862A2 (pt) formulações para vacinas para neoplasia
EA201790294A1 (ru) Средства на основе флагеллина и применения, включающие эффективную вакцинацию
CL2015001562A1 (es) Método para obtener una vacuna de mycoplasma.
MX2015010305A (es) Vacuna de combinacion para virus sincitial respiratorio e influenza.
EA202090699A3 (ru) Композиции, содержащие буфер, вакцины, которые содержат композиции, содержащие буфер, и пути их применения
GB2518813A (en) OMV vaccine against Burkholderia infections
BR112013025424A2 (pt) processos para produzir uma composição imunogênica, e para fabricar uma vacina, e, composição imunogênica
EA201590491A1 (ru) Иммуногенная композиция
UA116053C2 (uk) Застосування похідних бензоімідазолу-проліну
BR112015021523A8 (pt) composição de uma vacina contra a tosse convulsa acelular, e, usos da composição e de antígenos da bordetella pertussis
GB2539148A (en) Vaccine compositions
PL404247A1 (pl) Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
CO6361948A2 (es) Uso de antigeno de mycoplasma bovis
AR095669A1 (es) Toxinas, composiciones y métodos relacionados
UA116697C2 (uk) Композиція для запобігання зараженню видами роду mycoplasma
MX388525B (es) Métodos mejorados para inactivación de enterovirus, composiciones de vacuna con adsorción de adyuvante y reducida en dosis obtenida de los mismos.
IN2015KN00516A (pl)